A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
| Cardiology |
 MICHAEL WARD, MD, PhD, FRCPC, Assistant ProfessorDr. Ward’s education started with a passion for human genetics, and he completed an Honour’s BSc at McGill university while also working at the Montreal Genome Centre. He then pursed a PhD and MD at the University of Toronto. His doctoral thesis was on the use of progenitor cells genetically engineered to secrete vasoactive agents and regenerate cardiovascular tissues lacking blood supply. This lead to his involvement in clinical trials of cell therapy for cardiovascular diseases such of pulmonary hypertension and myocardial infarctions. Following his formal education, he then pursed his residency in internal medicine and then in cardiology in Toronto. He then completed his Interventional Cardiology training at University Health Network, focusing on complex interventions, haemodynamic support devices and interventions for hypertrophic cardiomyopathy (HCM). Dr. Ward’s clinical interests are in coronary artery disease (CAD), complex percutaneous coronary interventions (PCI), treatment of cardiogenic shock and in HCM. He is one of the founding members of the LHSC HCM Program, and has started a program for percutaneous septal reduction therapies for patients who are not candidates for surgery. Dr. Ward’s research interests include cardiac regeneration with stem/progenitor cell-based gene therapy. He is interested in how the bone marrow produces regenerative cells in the context of various clinical scenarios, such as chronic severe CAD, and following successful cardiac interventions. As a member of the HCM team, he is also involved in the development of a regional research program for the advancement of medical therapy for this disease. Keywords: Interventional Cardiology |
| Critical Care Medicine |
 CHARLES WEIJER, MD, PhD, ProfessorDr. Charles Weijer is a bioethicist and Professor of Medicine, Epidemiology & Biostatistics, and Philosophy. He is an internationally recognized expert in research ethics. His publications on the duty of care in clinical research, the ethical analysis of study benefits and harms, and empowering communities in research have been broadly influential. From 2008 to 2013, Dr. Weijer co-led a collaboration that produced the first international ethics guidelines for cluster randomized trials. From 2014 to 2018 he collaborated with Dr. Adrian M. Owen on a project exploring the ethics of functional neuroimaging after severe brain injury. Dr. Weijer led the writing team for the World Health Organization’s guidance on “Ethical Considerations for Health Policy and Systems Research,” published in 2019. In 2020, he served on the WHO Working Group for Guidance on Human Challenge Studies in COVID-19. Dr Weijer is currently working with Dr. Marat Slessarev and an interdisciplinary team to explore the ethics of research involving imminently dying patients, and ethical issues in organ donation, including the use of normothermic regional perfusion. Dr. Weijer held the Tier 1 Canada Research Chair in Bioethics from 2005 to 2019. In 2014, he received Western’s Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada. Keywords: Controlled human infection models Organ donation Randomized controlled trials Research Ethics |
| Nephrology |
 MATTHEW WEIR, MD, FRCPC, MSc, Associate ProfessorDr. Weir is a nephrologist at the London Health Sciences Centre and the Medical Director of the Kidney Care Centre. He treats patients with chronic kidney disease including those who require dialysis or transplantation. His research interests relate to the interactions between pharmaceutics, impaired renal function and hemodialysis. Dr. Weir is honoured to be a part of the multidisciplinary team at the Kidney Clinical Research Unit where he seeks to generate new knowledge that will improve the health of patients suffering with kidney disease. Keywords: Renal Pharmacoepidemiology Drug Safety |
| Gastroenterology |
 AZE WILSON, MD, PhD, FRCPC, Associate ProfessorDr. Wilson is a Royal College-certified clinical gastroenterologist and researcher at London Health Sciences Centre with a primary academic appointment to the Department of Medicine, Division of Gastroenterology. She treats patients with chronic gastrointestinal illnesses with a focus on inflammatory bowel disease. She has completed a doctorate degree in physiology and pharmacology and has cross-appointments to the Division of Clinical Pharmacology and the Department of Physiology & Pharmacology at Western University. Her research interests include factors affecting drug metabolism and drug response in inflammatory bowel disease. She also has an interest in biomarkers of drug response and disease severity as well as understanding the interplay between host genomics and drug response. Keywords: Biomarkers Drug adverse events Drug metabolism Drug response Inflammatory bowel diseases Pharmacogenomics |
